Title:
トール様受容体７またはトール様受容体９の活性化阻害剤
Document Type and Number:
Japanese Patent JP6856900
Kind Code:
B2
Abstract:
In the present invention, a compound selected from cyclobakuchiol A, cyclobakuchiol B and derivatives thereof, a pharmacologically acceptable salt thereof or a prodrug thereof, is a low molecular weight compound having an action of selectively inhibiting Toll-like receptor 7, or Toll-like receptor 9, and is useful as an active ingredient in an agent for preventing or treating a disease accompanying activation of Toll-like receptor 7, or Toll-like receptor 9.
More Like This:
| JP2006522807 | Topical L-carnitine composition |
| WO/2019/009663 | COMPOSITION FOR PREVENTING AND AMELIORATING ATHLETE'S FOOT |
| WO/2000/061189 | WATER-SOLUBLE COMPOSITIONS OF BIOACTIVE LIPOPHILIC COMPOUNDS |
Inventors:
Kiyoshi Takatsu
Yoshinori Nagai
Naoki Okamoto
Yuichi Kobayashi
Fujito Shigeto
Yoshinori Nagai
Naoki Okamoto
Yuichi Kobayashi
Fujito Shigeto
Application Number:
JP2017540014A
Publication Date:
April 14, 2021
Filing Date:
September 16, 2016
Export Citation:
Assignee:
National University Corporation Toyama University
National University Corporation Tokyo Institute of Technology
Teika Pharmaceutical Co., Ltd.
National University Corporation Tokyo Institute of Technology
Teika Pharmaceutical Co., Ltd.
International Classes:
A61K31/05; A61K31/085; A61K31/222; A61P1/02; A61P1/18; A61P5/14; A61P7/00; A61P7/06; A61P9/00; A61P9/10; A61P17/00; A61P17/06; A61P19/02; A61P21/00; A61P25/00; A61P29/00; A61P31/04; A61P31/12; A61P37/02; A61P37/06; A61P43/00; C07C39/19; C07C69/007
Other References:
BACKHOUSE C. Nadine et al.,Active constituents isolated from Psoralea glandulosa L. with antiinflammatory and antipyretic activities,Journal of Ethnopharmacology,2001年,Vol.78, No.1,pp.27-31
BACKHOUSE C. Nadine et al.,Cyclobakuchiols A and B from Psoralea Glandulosa,Phytochemistry,1995年,Vol.40, No.1,pp.325-327
BACKHOUSE C. Nadine et al.,Cyclobakuchiols A and B from Psoralea Glandulosa,Phytochemistry,1995年,Vol.40, No.1,pp.325-327
Attorney, Agent or Firm:
Ryu Iwatani